Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab PK/PD in Chinese Healthy Subjects
NCT02979015Phase 1Completed
- Sponsor
- Sanofi
- Start
- Nov 2016
- Primary completion
- Nov 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hypercholesterolemia comparing Alirocumab with Placebo (2 arms). Primary endpoints: Incidence of adverse events up to 12 weeks and Incidence of injection site reactions up to 4 days. Started Nov 2016; status: completed.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT02979015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02979015.